Obesity Clinical Trial
— VIDADOOfficial title:
Vascular and Metabolic Effects of Vitamin D Supplementation Associated With Lifestyle Management in Obese Adolescents: Prospective, Randomized, Controlled Trial
Verified date | June 2017 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of this study is to analyze in a population of obese adolescents, the effect of vitamin D3 supplementation in addition to lifestyle and dietary management on vascular function assessed by the change between M0 and M3 of endothelium-dependent vasorelaxation measured at the brachial artery (Flow-Mediated Dilation).
Status | Completed |
Enrollment | 49 |
Est. completion date | June 24, 2016 |
Est. primary completion date | June 24, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 11 Years to 17 Years |
Eligibility |
General Inclusion Criteria: - The patient's legal representatives must have given their informed and signed consent - The patient must be insured or beneficiary of a health insurance plan - Sexual maturation of at least Tanner stage 2 Inclusion criteria for the patient population - The subject has a body mass index corresponding to grade 2 obesity according to the curves described by Rolland-Cachera et al (1991) - Absence of at least 5% of total weight over the last 3 months Inclusion criteria for the control population - The subject has a body mass index < 90th percentile Exclusion Criteria: - The patient is participating in another study - The patient is in an exclusion period determined by a previous study - The patient is under judicial protection - The patient's legal representative(s) refuse(s) to sign the consent - It is impossible to correctly inform the patient or his/her legal representative(s) - The patient has a contraindication for physical activity (joint, heart or other) - The subject does at least 3 hours of extracurricular physical activity per week - The subject has a concomitant illness, a history of first-degree cardiovascular disease, abnormal glucose tolerance (pre-diabetes or diabetes). - Active smoking - Known dyslipidemia (particularly hypercholesterolemia). - The subject regularly takes food and vitamin supplements and refuses to stop taking these during the study (in case of disruption of these supplements, a wash-out stopping period of 3 weeks is required). - BMI corresponding to a grade 1 obesity according to the Rolland-Cachera et al. (1991) curves. - Secondary or known genetic obesity. - Known hypersensitivity to vitamin D. - Hypercalcemia, hypercalciuria, calcium lithiasis |
Country | Name | City | State |
---|---|---|---|
France | CHRU de Nîmes - Hôpital Universitaire Carémeau | Nîmes Cedex 09 | |
France | Institut Saint Pierre | Palavas-Les-Flots |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes | EA4278 PEC Laboratoire de Pharm-Ecologie Cardiovasculaire, UMR1260 NORT Nutrition, Obésité et Risque Thrombotique |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in Flow Mediated Dilation (%) at the brachial artery | 3 months | ||
Secondary | Change from baseline in Nitrate Mediated Dilation (%) at the brachial artery | 3 months | ||
Secondary | Change from baseline in carotid compliance (mm^2mmHg^-1) | 3 months | ||
Secondary | Change from baseline in brachial compliance (mm^2mmHg^-1) | 3 months | ||
Secondary | Change from baseline in arterial wave speed (m*s^-1) | 3 months | ||
Secondary | Usual Vitamin D intake according to food questionnaire | Baseline | ||
Secondary | Change from baseline in blood 25(OH)D levels (mmol*L^-1) | 3 months | ||
Secondary | Change from baseline in blood parathyroid hormone levels (mmol*L^-1) | 3 months | ||
Secondary | Change from baseline in serum calcium levels (mmol*L^-1) | 3 months | ||
Secondary | Change from baseline in blood total protein levels (g*L^-1) | 3 months | ||
Secondary | Change from baseline in Homeostatic model assessment Insulin Resistance | 3 months | ||
Secondary | Change from baseline in the ratio Low Density Lipoprotein/High Density Lipoprotein | 3 months | ||
Secondary | Change from baseline in Triglyceride levels | 3 months | ||
Secondary | Change from baseline in Acetylcholine-Cutaneous Blood Flow peak | 3 months | ||
Secondary | Change from baseline in Sodium nitroprussiate-Cutaneous Blood Flow peak (%) | 3 months | ||
Secondary | Change from baseline in Insulin-Cutaneous Blood Flow peak (%) | 3 months | ||
Secondary | Change from baseline in TNF-alpha (pg*mL^-1) | 3 months | ||
Secondary | Change from baseline in IL-6 (pg*mL^-1) | 3 months | ||
Secondary | Change from baseline in High sensitivity C-reactive protein (pg*mL^-1) | 3 months | ||
Secondary | Change from baseline in leptin (pg*mL^-1) | 3 months | ||
Secondary | Change from baseline in adiponectin (pg*mL^-1) | 3 months | ||
Secondary | Change from baseline in SuperOxyde Dismutase (U*gHb^-1) | 3 months | ||
Secondary | Change from baseline in Isoprostanes (ng*L^-1) | 3 months | ||
Secondary | Change from baseline in nitrite-nitrate (µmol*L^-1) | 3 months | ||
Secondary | Change from baseline in PAI-1 (µmol*L^-1) | 3 months | ||
Secondary | Metabolomic profile | baseline | ||
Secondary | Metabolomic profile | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |